Geron Q1 net loss $55.4M ($0.09/shr); PDUFA for imetelstat June 16, 2024

GERON CORP

2024-Q1 EPS reported -$0.09 revenue$304,000

Q1 net loss of $55.4M ($0.09/shr) vs $38.1M ($0.07/shr) in Q1 2023; revenue $304K.
Cash and marketable securities $465M as of March 31, 2024; $80M principal debt outstanding.
FDA ODAC voted 12-2 in favor of imetelstat benefit/risk for lower-risk MDS; PDUFA date June 16, 2024.
IMpactMF trial timelines extended 6 months: interim analysis now early 2026, final early 2027.
FY2024 total operating expense guidance $270M-$280M; commercial team onboarded in April.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.